Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.24
+0.8%
$22.88
$13.15
$27.72
$12.17B1.695.45 million shs652,928 shs
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$14.55
$14.55
$9.20
$18.67
$6.84B0.32121 shs16 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+5.02%-2.39%+12.17%+5.03%+69.10%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.00%0.00%0.00%+3.93%+37.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.24
+0.8%
$22.88
$13.15
$27.72
$12.17B1.695.45 million shs652,928 shs
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$14.55
$14.55
$9.20
$18.67
$6.84B0.32121 shs16 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+5.02%-2.39%+12.17%+5.03%+69.10%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.00%0.00%0.00%+3.93%+37.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.2016.35% Upside
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest ELAN and OPHLF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/11/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
DowngradeSell (D+)Sell (D)
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$30.00 ➝ $31.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetOverweight$28.00 ➝ $30.00
4/27/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UpgradeSell (D)Sell (D+)
4/17/2026
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
UpgradeHold
4/15/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Initiated CoverageBuy$30.00
3/27/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Reiterated RatingSell (D+)
(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.57$2.46 per share9.86$13.18 per share1.84
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$3.43B2.00$1.08 per share13.50$11.07 per share1.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A19.871.50-4.95%7.42%3.66%8/6/2026 (Estimated)
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$463.46M$0.9914.7017.74N/A13.51%8.55%6.58%8/3/2026 (Estimated)

Latest ELAN and OPHLF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.10
3.02
2.56

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/A

Insider Ownership

CompanyInsider Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
4,287469.91 millionN/ANot Optionable

Recent News About These Companies

ONO-4685 by Ono Pharmaceutical for T-Cell Lymphomas: Likelihood of Approval

New MarketBeat Followers Over Time

Media Sentiment Over Time

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$24.24 +0.19 (+0.78%)
As of 11:13 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Ono Pharmaceutical stock logo

Ono Pharmaceutical OTCMKTS:OPHLF

$14.55 0.00 (0.00%)
As of 06/9/2026

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.